key: cord-0711130-tx1dhtdz
authors: Wilbers, Thom J.; Koning, Mark V.
title: Renal replacement therapy in critically ill patients with COVID-19: A retrospective study investigating mortality, renal recovery and filter lifetime
date: 2020-07-30
journal: J Crit Care
DOI: 10.1016/j.jcrc.2020.07.025
sha: 39883f00efb12b0b4e43f77b56a7171c90037d21
doc_id: 711130
cord_uid: tx1dhtdz

PURPOSE: This study aims to investigate mortality and renal recovery in patients with Acute Kidney Injury (AKI) and Renal Replacement Therapy (RRT) due to COVID-19. A secondary aim is to investigate the filter life time in Continuous VenoVenous Hemofiltration (CVVH) and the effect of different methods of anticoagulation. METHODS: All patients with COVID-19 infection admitted to the ICU between March 16th 2020 to May 10th 2020 were retrospectively studied. Patients were categorized in a AKI-group and a non-AKI-group. RESULTS: Thirty-seven patients were included. Twenty-two (60%) patients developed AKI. Mortality in the AKI-group was 41% compared to 20% in the non-AKI group, p = 0.275. Comparable mortality was seen in the RRT (39%) and the non-RRT group (44%), p = 1.000. Renal function recovered to a KDIGO-stage 1 in 64% of the patients with AKI when discharged from the ICU. Life time for the CVVH filters (n = 53) was 27 h (14–63)[2–78]. No difference was found with various methods of anticoagulation. CONCLUSION: The need for RRT in critically ill patients with COVID-19 was reversible in our cohort and RRT was not associated with an increased mortality compared to AKI without the need for RRT. Higher levels of anticoagulation were not associated with prolonged filter life.

Dear editor, Acute Kidney Injury (AKI) complicates a COVID-19 infection in up to 30% of the patients. [1] [2] [3] [4] [5] [6] [7] The need for Renal Replacement Therapy (RRT) varied from 2-22%. [8] [9] [10] [11] [12] Reported mortality rates for patients with RRT varies from 51.6-100%. [6] [7] [8] [13] [14] These mortality rates might suggest that renal replacement therapy appears to be prognostically important, especially when resources are limited. In addition, due to the thrombogenicity of the patients suffering from COVID-19, filter life may be shorter due to filter clotting. [15] The aim of this study was to investigate the mortality-rate and renal recovery in patients with AKI due to COVID-19. A secondary aim was to investigate the filter life times and the effect of different anticoagulants.

All patients admitted to the Intensive Care Unit (ICU) of the Rijnstate Hospital in Arnhem, The Netherlands from March 16 th 2020 to May 10 th 2020 were retrospectively studied. Follow-up lasted until May 13 th 2020.

Inclusion criterium was a positive COVID-19 Polymerase Chain Reaction (PCR). Exclusion criterium was an admission shorter than 24 hours. Ethical approval and requirement for written informed consent was not required due to the retrospective and non-interventional nature of the study.

All patients with COVID-19 were admitted to the ICU for respiratory failure. All patients received thromboprophylaxis with daily nadroparin 2800 IE s.c., which was increased to 5600 IE s.c. daily following national guidelines on April 10 th , 2020.When AKI occurred, post-renal and pre-renal causes were excluded.

CRRT was started on indication, such as hyperkaliemia, fluid overload unresponsive to diuretics and severe metabolic acidosis . RRT was not an indication for ICU-admission, since a dialysis unit is available.

In our institution the primary method of RRT is Continuous VenoVenous Hemofiltration (CVVH) anticoagulated with citrate. When patients receive systemic anticoagulation with heparin for another indication, a bicarbonate-buffered substitution fluid is chosen and heparin is targeted at an APTT of 50-70 seconds. A filter change is scheduled routinely after 72 hours. Intermittent Hemodialysis (IHD) is the secondary modality.

The indication for RRT is evaluated with every filter change. RRT is only restarted if clearance or diuresis, with diuretics if needed, is deemed insufficient by the treating physician.

The patients were categorized in a AKI-group, defined by a KDIGO-stage 1, 2 and 3 and a non-AKI-group. The patients from the AKI-group were categorized in a RRT-group and a non-RRT-group. All data are presented as median (interquartile range)[minimum-maximum]. 95% Confidence Interval (95%CI) was calculated for J o u r n a l P r e -p r o o f Journal Pre-proof proportions. The Mann-Whitney-U-test was used to compare continuous data between groups, the Fisher's exact test was used for categorical data. A p< 0.05 was considered significant.

A total of 39 patients were admitted to the ICU for COVID-19. 37 patients were included for analysis, of which 6 (16%) patients were still admitted to the ICU on May 13 th .

Twenty-two (60%, 95%CI: 42-75) patients developed AKI. Hypertension, diabetes mellitus and chronic kidney disease were more frequent present in the AKI group, albeit not reaching significance. The severity of illness was comparable between the AKI and non-AKI group, except for a higher level of creatinine in the AKI-group upon admission. Mortality tended to be increased in the AKI-group (41%, 95%CI: 20-64) compared to the non-AKI-group (20%, 95%CI: 0-40). Of the AKI-group patients, renal function recovered in 64% to a KDIGO-stage 1 upon discharge from ICU.

Thirteen of the 22 patients with AKI (59%, 95%CI: 36-79) were treated with RRT. The patients in the RRTgroup were younger, had higher levels of creatinine and BUN and oliguria was more frequently present compared to the non-RRT group. RRT was initiated a median of 6 days (4-12) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] after ICU admission and lasted for 7 days (4-9) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . All patients received CVVH and five received at least one session of IHD. The indication for starting RRT were acidosis (n=4), hyperkaliemia (n=7) and fluid overload (n=2).

Comparable mortality rates were seen in the RRT (39%, 95%CI:14-68) versus non-RRT group (44%, 95%CI:14-79), p=1.000. Four patients that did not survive in the RRT-group needed RRT until death. The KDIGO-stages on discharge were comparable between the groups. None of the patients required RRT after ICU discharge.

Fifty-three filters were used for CVVH and filter lifetime was 27 hours (14-63) , 35 (66%) of which were regional anticoagulated with citrate. Thirty filters (57%) failed prematurely and the lifetime of these filters was 21 hours (13-33) . No data were available regarding cause of failing. No correlation was found between the The current study shows a mortality rate of 39% in patients with RRT for COVID-19 associated AKI, which strengthens the likelihood of a mortality around the lower limit of the reported 51.6-100%. [6] [7] [8] [13] [14] Second, J o u r n a l P r e -p r o o f Journal Pre-proof renal function recovered to KDIGO-stage 1 in 64% of the patients with AKI when discharged from the ICU. This is merely a suggestion of renal recovery, since no long-term data are available. One can conclude, however, that RRT is a temporary intervention and associated with similar short term mortality rates as patients with AKI without RRT. Furthermore, the low filter lifetimes were not associated with anticoagulation. Other reasons for a reduced filter lifetime may be increased filter clogging due to inflammatory proteins, a late response to alarms by the nursing staff due to personal protection equipment requirements or the decreased catheter performance due to prone positioning.

In conclusion, the need for RRT for AKI in critically ill patients with COVID-19 was often temporary in our cohort and was not associated with an increased mortality rate compared to AKI without the need for RRT. This could imply that no threshold for initiating RRT based on futility of treatment is warranted. This study found no support for the use of higher levels of anticoagulation to prolong the low filter lifetime.

Funding: not applicable.

Acute kidney injury in SARS-CoV-2 infected patients

Kidney disease is associated with in-hospital death of patients with COVID-19

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

The Novel Coronavirus 2019 epidemic and kidneys

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Clinical predictors of mortality due to COVID-19 based on an

Clinical Course and Outcomes of 344 Intensive Care Patients with COVID

Hospitalization and Critical Care of 109 Decedents with COVID-19

Acute kidney injury in patients hospitalized with COVID-19

Intensive Care National Audit and Research Centre (ICNARC)

COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure

J o u r n a l P r e -p r o o f